Marta Mosca

Oct 5, 2024 | ard.bmj.com | Marta Mosca |George Bertsias |David Isenberg |Annegret Kuhn

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sep 1, 2024 | jrheum.org | Marco Di Battista |Alessandra Della Rossa |Marta Mosca |M. Di Battista

Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy Marco Di Battista, Alessandra Della Rossa, Marta Mosca The Journal of Rheumatology Sep 2024, 51 (9) 899-903; DOI: 10.3899/jrheum.2024-0103

Jun 24, 2024 | jrheum.org | Marco Di Battista |Marta Mosca |M. Di Battista |Rheumatology Unit

AbstractObjective Raynaud phenomenon (RP) and digital ulcers (DUs) are the main signs of digital vasculopathy in systemic sclerosis (SSc). Selexipag is an oral prostacyclin agonist approved for SSc-related pulmonary arterial hypertension. Following our previous preliminary short-course report, we herein present long-term data on selexipag safety and efficacy in the treatment of SSc digital vasculopathy.

Jun 7, 2024 | jrheum.org | Marco Di Battista |Alessandra Della Rossa |Marta Mosca |M. Di Battista

Long-term data on efficacy and safety of selexipag for scleroderma digital vasculopathy Marco Di Battista, Alessandra Della Rossa, Marta Mosca The Journal of Rheumatology Jun 2024, jrheum.2024-0103; DOI: 10.3899/jrheum.2024-0103